A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.
J. D. Peyton
No relevant relationships to disclose
J. Rodon Ahnert
No relevant relationships to disclose
H. Burris
No relevant relationships to disclose
C. Britten
No relevant relationships to disclose
L. C. Chen
No relevant relationships to disclose
J. Tabernero
Consultant or Advisory Role - Novartis
V. Duval
Employment or Leadership Position - Novartis
N. Rouyrre
Employment or Leadership Position - Novartis
A. P. Silva
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
C. Quadt
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. Baselga
Consultant or Advisory Role - Novartis